ArticleNature communications2019
Synthetic chimeric nucleases function for efficient genome editing.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A self-iterative orthogonal base-editing platform enables multiplex N-to-N diversification and genome-scale functional screening in Escherichia coli.Nucleic acids research · 2026Article
- Engineering a High-Fidelity MAD7 Variant with Enhanced Specificity for Precision Genome Editing via CcdB-Based Bacterial Screening.Biomolecules · 2025Article
- SELECT: high-precision genome editing strategy via integration of CRISPR-Cas and DNA damage response for cross-species applications.Nucleic acids research · 2025Article
- Review
- A MAD7-based genome editing system for Escherichia coli.Microbial biotechnology · 2023Article
- Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research.Military Medical Research · 2023Review
- Expanding the genome editing toolbox of Saccharomyces cerevisiae with the endonuclease ErCas12a.FEMS yeast research · 2023Article
- Recalcitrance to transformation, a hindrance for genome editing of legumes.Frontiers in genome editing · 2023Review
- CRISPR-Cas12a nucleases function with structurally engineered crRNAs: SynThetic trAcrRNA.Scientific reports · 2022Article
- Advances in S gene targeted genome-editing and its applicability to disease resistance breeding in selectedBioengineered · 2022Article
- Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity.BMC biology · 2022Article
- CABE-RY: A PAM-flexible dual-mutation base editor for reliable modeling of multi-nucleotide variants.Molecular therapy. Nucleic acids · 2021Article
- UnlockingGenes · 2021Article
- Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases.Nature communications · 2021Article
- A more efficient CRISPR-Cas12a variant derived fromMolecular therapy. Nucleic acids · 2021Article
- CRISPR technologies and the search for the PAM-free nuclease.Nature communications · 2021Review
- The Model SystemLife (Basel, Switzerland) · 2020Review
- Enhancement of target specificity of CRISPR-Cas12a by using a chimeric DNA-RNA guide.Nucleic acids research · 2020Article
- CRISPR-based strategies for targeted transgene knock-in and gene correction.Faculty reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR-Cas systems have revolutionized genome editing across a broad range of biotechnological endeavors. Many CRISPR-Cas nucleases have been identified and engineered for improved capabilities. Given the modular structure of such enzymes, we hypothesized that engineering chimeric sequences would generate non-natural variants that span the kinetic parameter landscape, and thus provide for the rapid selection of nucleases fit for a particular editing system. Here, we design a chimeric Cas12a-type library with approximately 560 synthetic chimeras, and select several functional variants. We demonstrate that certain nuclease domains can be recombined across distantly related nuclease templates to produce variants that function in bacteria, yeast, and human cell lines. We further characterize selected chimeric nucleases and find that they have different protospacer adjacent motif (PAM) preferences and the M44 chimera has higher specificity relative to wild-type (WT) sequences. This demonstration opens up the possibility of generating nuclease sequences with implications across biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.